Research analysts at Sanford C. Bernstein started coverage on shares of Humana (NYSE:HUM – Get Rating) in a research report issued to clients and investors on Thursday, The Fly reports. The firm set a “market perform” rating on the insurance provider’s stock.
Other equities research analysts have also recently issued research reports about the company. SVB Leerink cut their price target on Humana from $528.00 to $525.00 and set an “outperform” rating for the company in a research note on Thursday, February 3rd. Truist Financial upped their price target on Humana from $460.00 to $490.00 in a research note on Thursday, April 7th. Deutsche Bank Aktiengesellschaft upped their price target on Humana from $418.00 to $435.00 in a research note on Thursday, February 3rd. Morgan Stanley upped their price target on Humana from $410.00 to $436.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 9th. Finally, StockNews.com upgraded Humana from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, April 20th. Eight investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $486.38.
HUM traded up $7.53 on Thursday, reaching $452.22. The company’s stock had a trading volume of 493,015 shares, compared to its average volume of 1,190,597. The stock has a 50 day moving average of $442.31 and a two-hundred day moving average of $432.88. The company has a quick ratio of 1.53, a current ratio of 1.53 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $57.20 billion, a price-to-earnings ratio of 19.19, a P/E/G ratio of 1.28 and a beta of 0.86. Humana has a fifty-two week low of $351.20 and a fifty-two week high of $472.68.
In related news, insider Timothy S. Huval sold 3,477 shares of the stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $443.14, for a total value of $1,540,797.78. Following the completion of the sale, the insider now directly owns 5,768 shares of the company’s stock, valued at approximately $2,556,031.52. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO William Kevin Fleming sold 3,210 shares of the stock in a transaction dated Thursday, April 28th. The stock was sold at an average price of $449.68, for a total value of $1,443,472.80. Following the completion of the sale, the chief accounting officer now directly owns 884 shares of the company’s stock, valued at $397,517.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,644 shares of company stock valued at $4,702,360. 0.39% of the stock is currently owned by company insiders.
A number of hedge funds have recently modified their holdings of HUM. Tcwp LLC acquired a new position in Humana in the 1st quarter worth about $25,000. Bell Investment Advisors Inc acquired a new position in shares of Humana during the 3rd quarter valued at about $26,000. Spire Wealth Management acquired a new position in shares of Humana during the 4th quarter valued at about $30,000. BerganKDV Wealth Management LLC boosted its stake in Humana by 885.7% during the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 62 shares during the period. Finally, Riverview Trust Co bought a new stake in Humana during the 1st quarter valued at approximately $32,000. 94.93% of the stock is currently owned by institutional investors.
Humana Company Profile (Get Rating)
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.
- Get a free copy of the StockNews.com research report on Humana (HUM)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.